Lucentis Generic Name & Formulations
Ranibizumab 6mg/mL (0.3mg), 10mg/mL (0.5mg); soln for oph intravitreal inj; preservative-free.
Vascular endothelial growth factor (VEGF) inhibitor.
Single-use prefilled syringe, single-use vial—1
Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Diabetic macular edema (DME). Diabetic retinopathy (DR). Myopic choroidal neovascularization (mCNV).
Lucentis Dosage and Administration
Give by intravitreal inj. AMD: 0.5mg once a month (approx. 28 days); or 3 monthly doses followed by less frequent dosing (less effective); or 0.5mg every 3 months after 4 monthly doses (less effective). Monitor regularly. RVO: 0.5mg once a month (approx. 28 days). DME, DR: 0.3mg once a month (approx. 28 days). mCNV: 0.5mg once a month (approx. 28 days) for up to 3 months; may retreat if needed.
Ocular or periocular infections.
Lucentis Boxed Warnings
Monitor intraocular pressure prior to and 30mins after inj. Monitor for perfusion of optic nerve and for infection following the inj (endophthalmitis and retinal detachments possible). Pregnancy; may cause embryo-fetal toxicity. Nursing mothers.
Lucentis Adverse Reactions
Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, intraocular inflammation; rare: arterial thromboembolic events, fatal events (with DME, DR).
Lucentis Clinical Trials
Lucentis Patient Counseling